Boston Scientific greatly increases number of recalled stents

Boston Scientific expanded the recall of its Taxus drug-coated stents from an initial 200 to 85,000 because of problems that occur during the implant procedure, but said patients who have already had stents successfully implanted should not be concerned. Several hospitals said they are suspending use of the stent until assured the problems have been corrected. The firm also said it would delay release of second-quarter results and probably faces a $45 million reduction in sales and a $50 million write-off of inventory.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Systems Test - V&V Engineer - 14000008LS
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
Multiple Locations, SL_Multiple Locations
Director, Antibiotics and Innovation Project
The Pew Charitable Trusts
Washington, DC